

ABOUT THE STUDY

NEULARK is an innovative clinical trial design for people with Parkinson's disease. The study will evaluate the safety and efficacy of NEU-411, an investigational treatment for a genetically-defined subset of people with Parkinson's disease.

This study design uses new technologies to track the symptoms and disease progression of participants, while minimizing the burden of participating in a clinical trial.

Participating in a research study is an opportunity to contribute to medical progress. Your involvement can make a significant difference in the lives of many.

Eligibility for participation in a research study is determined by meeting specific criteria. The study team will thoroughly review your medical history and current health to see if they match the eligibility requirements. They will assess if you qualify to take part in the study.

For more information, please visit our study website: neulark.com



Sponsored by

Neuron23, Inc.
343 Oyster Point Boulevard, Suite 120
South San Francisco, CA 94080

Neuron23 and Neulark are trademarks of Neuron23, Inc.

NEU-411-250001 v1 07/2025

The Neulark logo features the word "Neulark" in a white serif font against a dark green background of a forest. A small white bird icon is perched on the letter "l".

Neulark



A NEW DAY FOR PEOPLE WITH PARKINSON'S DISEASE

AM I ELIGIBLE?

BASIC ELIGIBILITY CRITERIA

AGE: Between 40 and 80 years.

DIAGNOSIS: Have received a diagnosis of Parkinson's disease by a neurologist.

MEDICATION: No anticipated need for dopamine medicines during the study.

HEALTH STATUS: Generally good health.

DETERMINING ELIGIBILITY

INITIAL SCREENING: Review your medical history and current health status.

GENETIC TESTING: Confirm LRRK2 overactivity (LRRK2-driven status).

MEDICAL EVALUATION: Undergo a comprehensive exam to ensure you meet health criteria.

NEULARK STUDY

Clinical trials are carefully designed scientific investigations conducted to answer specific questions.

NEULARK will investigate whether NEU-411 can slow Parkinson's Disease progression. NEU-411 is taken orally and is designed to inhibit LRRK2 overactivity.

By joining the NEULARK study, you will:

- Contribute to vital medical research.
- Receive close study-related monitoring and care from a team of specialists.
- Potentially benefit from an investigational treatment targeting LRRK2-driven Parkinson's disease.

Like all clinical trials, there are potential risks. Our team will provide comprehensive information to help you make an informed decision.



WHAT IS LRRK2-DRIVEN PARKINSON'S DISEASE?

PARKINSON'S DISEASE

Parkinson's disease is a complex condition that primarily affects the brain and leads to a range of symptoms. These symptoms can impact your movements (like tremors and muscle stiffness) and have non-movement effects such as depression and sleep problems.

LRRK2 PARKINSON'S DISEASE

In some people with Parkinson's disease, LRRK2 (short for leucine-rich repeat kinase 2) is known to play a key role. Even if you don't have a family history of Parkinson's disease, LRRK2 may still be involved. When the LRRK2 pathway is overactive, it can lead to damage in the brain that causes Parkinson's disease symptoms.

